Please ensure Javascript is enabled for purposes of website accessibility

This Common Dietary Ingredient May Increase Breast Cancer and Lung Metastasis Risk

By Sean Williams - Jan 10, 2016 at 9:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

According to a recent study, 30% of mice in a controlled group developed breast cancer after six months compared to 50%-58% of mice that were given this ingredient commonly found in your kitchen.

Cancer cells dividing. Image source: National Cancer Institute. 

Globally, cancer doesn't even rank in the top 10 in terms of causes of death as of 2012, per the World Health Organization. But the mystery and ultimately high mortality rate of some cancer types makes it potentially the most dangerous up and coming disease threat.

A global cancer threat looms
The World Health Organization predicts that cancer rates will rise by nearly 60% over a two-decade period to 22 million annual diagnoses from 14 million. Some of this rise actually is good news, because old age is one of the few common risk factors across nearly all cancer types. A rising incidence rate suggests people are living longer, which in turn means that improved global access to medicine and healthcare is making an impact.

But, the opposite side of this coin is the idea of having to deal with rising rates of cancer. Some common cancer types, such as prostate cancer, melanoma, and breast cancer, have witnessed their five-year survival rates push into the 90th percentile over the past three-plus decades. Other cancer types, though, such as lung cancer and pancreatic cancer, have witnessed only minimal improvements since 1975-1977. 

But, as researchers have suggested, it's often not the original tumor that winds up killing a cancer patient, but the metastasis of cancer to other parts of the body that makes the disease incredibly difficult to treat. Understanding the triggers behind metastasis could allow researchers a treasure trove of knowledge that could be used for preventative or treatment purposes.

This dietary ingredient could be a trigger for breast cancer and lung metastasis
One commonly hypothesized "trigger" of cancer metastasis that researchers have been focused on for years is an item found in basically every American household: sugar. Sugar is a source of energy for healthy cells in our bodies, but researchers have long postulated that it could also be the energy source that kicks cancer cells into overdrive. However, proving this hypothesis has been a challenge -- until now.

Image source: Pixabay.

According to a research study released on Dec. 31, by the University of Texas MD Anderson Cancer Center, and published on New Year's Day in online journal Cancer Research, the high amounts of dietary sugar found in Western diets may increase the risk of breast cancer, as well as cancer metastasis to the lungs.

How did researchers at the MD Anderson Cancer Center come to this conclusion? They tested their hypothesis on mice, giving them levels of sucrose that were as similar as possible to the amount that would be consumed in a Western diet. Researchers also used mice that were genetically predisposed to breast cancer in order to mimic the genetic markers for predisposition that you'd find with some humans.

Image source: National Cancer Institute.

The results showed that when the mice were six months old, 30% of those fed a starch-dominant diet had breast cancer compared to a range of 50% to 58% of mice in the sugar-rich cohorts which had mammary tumors by the same age. Researchers concluded that fructose (the two components of sucrose are glucose and fructose) was the "ingredient," so to speak, that really facilitated breast cancer development and inflammation that's believed to have led to breast cancer development. Fructose is commonly found in table sugar as well as high-fructose corn syrup, a liquid sweetener.

Additionally, researchers concluded that high consumption of fructose led to a greater propensity for cancer metastasis to the lungs in tested mice compared to the mice on the starch-based diet. This is noteworthy, since localized cancer is often considerably easier to treat than a globalized cancer.

What's really notable about this study is that it was the first of its kind in animals to demonstrate that there may be a link between sugar consumption and cancer development/metastasis. As is typical of most initial studies, like the one from MD Anderson Cancer Center, researchers suggested additional follow-up studies be conducted.

Prevention, detection, and medication are the keys to success
If additional studies do conclude that fructose is one external factor that leads to a higher risk of cancer development and metastasis, then it'll allow researchers and the Food and Drug Administration the ability to bring this information to the public for all to see. Educating the public about cancer risk factors doesn't happen overnight, but the Centers for Disease Control and Prevention's war on tobacco, for instance, has been very successful in reducing adult smoking rates over the past 50 years. Smoking tobacco, as you're likely aware, comes with a higher risk of lung cancer and/or cardiovascular disease, and educating the public has done wonders in reducing these risks.

Image source: Myriad Genetics.

But, beyond just taking preventative measures, it's a call for diagnostic developers and drugmakers to work even harder at creating personalized therapies that can aid with the early detection of cancer, as well as the treatment of early stage and metastatic disease.

One prime example in the diagnostic setting is Myriad Genetics (MYGN 3.41%) with its BRACAnalysis gene test. Myriad's relatively inexpensive test allows women to discover whether or not they're carriers of the mutant BRCA1 or BRCA2 gene. Both mutations are associated with a higher risk of developing breast and ovarian cancer. Being a carrier of the mutant gene doesn't guarantee cancer development, but it would be a reason for women who do test positive to get regularly screened for cancer.

Perhaps the most famous BRACAnalysis client is Hollywood actress Angelina Jolie, whose mother died at a relatively young age from ovarian cancer. In total, Jolie has lost eight family members to cancer (typically breast or ovarian cancer). Jolie has taken the preventative measures of undergoing a mastectomy and having her ovaries and fallopian tubes removed in order to lower her risk of cancer development as much as possible.

Image source: Bristol-Myers Squibb.

As it pertains to fighting cancer with pharmaceuticals, all eyes are focused on the potential of cancer immunotherapies. One of cancer's greatest tricks is that it can grow almost undetected by the immune system. Immunotherapies look to change that by masking the immunosuppressant nature of cancer cells, which in turn gives your immune system a fighting chance.

Two prime examples here are Merck's (MRK 2.35%) Keytruda and Bristol-Myers Squibb's (BMY 1.49%) Opdivo, which are both currently approved to treat a type of metastatic melanoma and advanced non-small cell lung cancer patients. These two immunotherapies are geared to work best in patients whose tumors express PD-L1, with response rates in advanced NSCLC patients with high levels of PD-L1 expression basically doubling the previous standard of care. Merck's Keytruda and Bristol-Myers Squibb's Opdivo are both being separately studied in more than two dozen ongoing solid tumor trials.

As an investor of nearly two-decades, this an exciting time in the healthcare sector. But, as a person who lost their mother to cancer, it's even more encouraging to witness the progress being made on the scientific front at all levels of research in the fight against cancer.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$91.02 (2.35%) $2.09
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$75.57 (1.49%) $1.11
Myriad Genetics, Inc. Stock Quote
Myriad Genetics, Inc.
$27.61 (3.41%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.